WO2021100585A1 - キメラ抗原受容体遺伝子改変リンパ球の調製方法 - Google Patents

キメラ抗原受容体遺伝子改変リンパ球の調製方法 Download PDF

Info

Publication number
WO2021100585A1
WO2021100585A1 PCT/JP2020/042187 JP2020042187W WO2021100585A1 WO 2021100585 A1 WO2021100585 A1 WO 2021100585A1 JP 2020042187 W JP2020042187 W JP 2020042187W WO 2021100585 A1 WO2021100585 A1 WO 2021100585A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
antibody
preparation
culture
car
Prior art date
Application number
PCT/JP2020/042187
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
信博 西尾
義行 ▲高▼橋
Original Assignee
国立大学法人東海国立大学機構
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人東海国立大学機構 filed Critical 国立大学法人東海国立大学機構
Priority to JP2021558324A priority Critical patent/JPWO2021100585A1/ja
Publication of WO2021100585A1 publication Critical patent/WO2021100585A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Definitions

  • the present invention relates to genetically modified lymphocytes expressing chimeric antigen receptors (CAR transgenic lymphocytes). Specifically, the present invention relates to a method for producing CAR gene-introduced lymphocytes, uses of the cells, and the like.
  • CAR transgenic lymphocytes chimeric antigen receptors
  • CAR-T therapy Genetically modified T cell therapy
  • CAR-NK therapy genetically modified NK cell therapy
  • CAR-NK therapy genetically modified NK cell therapy
  • CAR typically comprises a structure in which the single-chain variable region of an antibody is the extracellular domain, which is linked to the transmembrane domain, the CD3 ⁇ , and the intracellular domain of the molecule that transmits the co-stimulation signal.
  • CAR transgenic lymphocytes are activated by binding to the antigen according to the specificity of the antibody, damaging target cells (such as cancer cells).
  • CAR therapy has advantages such as relatively easy cell preparation, high cytotoxic activity, and long-lasting effect, and is particularly resistant to refractory and conventional treatments.
  • CAR for the CD19 antigen expressed on the cell surface is gene-introduced into peripheral blood T cells collected from the patients, cultured, and infused.
  • the test has been conducted in Europe and the United States, and good results with a remission rate of 80 to 90% have been reported (Non-Patent Documents 1 to 3).
  • CAR therapy is attracting attention as one of the most promising treatments for refractory cancer in the United States.
  • Non-Patent Document 4 Non-Patent Document 4
  • the transposon method which is one of the gene modification techniques using non-viral vectors
  • the transposon method enables permanent gene transfer like the viral vector method
  • the gene transfer efficiency is lower than that of the viral vector method, and it is suitable for gene transfer operations (electroporation and its improvement methods, etc.).
  • the cells are damaged, and there is a problem that the cell viability and the cell proliferation rate decrease.
  • the research group of the present inventors said, "Protecting lymphocytes after CAR gene transfer by co-culturing with activated T cells prepared separately, gene transfer efficiency and cells.
  • the main object of the present invention is to provide a novel preparation (culture) means for increasing the number of CAR cells, and to contribute to the progress of clinical application of CAR therapy and the improvement of therapeutic results.
  • the present inventors have two strategies, that is, a method of stimulating cells after CAR gene transfer (CAR cells) with an anti-iditope antibody (first strategy), and We have created a method (second strategy) for stimulating cells after CAR gene transfer (CAR cells) with cells expressing the target antigen.
  • the first strategy is to directly stimulate CAR cells with anti-iditope antibodies, and CAR cell-specific proliferation can be expected.
  • a significant increase in the number of CAR cells improved in gene transfer efficiency / cell proliferation rate
  • was observed as compared with the conventional method stimulation with anti-CD3 antibody / anti-CD28 antibody
  • the second strategy stimulation by the target antigen is added during the culture of CAR cells, and CAR cell-specific proliferation can be expected as in the first strategy.
  • the two new strategies make it possible or facilitate to secure the number of cells required for treatment, and their clinical significance is extremely large.
  • the inventions shown below are based on these two strategies.
  • a method for preparing a genetically modified lymphocyte expressing a chimeric antigen receptor which comprises the following steps (1) to (3): (1) A step of preparing a genetically modified lymphocyte into which a target antigen-specific chimeric antigen receptor gene has been introduced; (2) The genetically modified lymphocyte prepared in step (1) is used in the presence of an anti-iditope antibody against the antigen recognition region of the chimeric antigen receptor on which it is expressed, or the target antigen of the chimeric antigen receptor on which it is expressed. The step of culturing in the presence of expressing cells; and (3) the step of collecting the genetically modified lymphocytes after culturing.
  • step (2) is performed after 8 to 48 hours have passed from the operation of introducing the target antigen-specific chimeric antigen receptor gene in step (1).
  • step 5 The preparation method according to any one of [1] to [4], wherein the culture period of step (2) is 1 to 14 days.
  • [6] The preparation method according to any one of [1] to [5], wherein the culture in step (2) is not stimulated by the anti-CD3 antibody and the anti-CD28 antibody.
  • [7] The preparation method according to any one of [1] to [6], wherein the anti-iditope antibody is a solid phase antibody or a beaded antibody.
  • Any of [1] to [7], wherein the genetically modified lymphocyte of step (1) can be obtained by introducing a target antigen-specific chimeric antigen receptor gene into a cell population containing T cells or progenitor cells thereof.
  • [9] The preparation method according to [8], wherein the cell population is peripheral blood mononuclear cells (PBMCs).
  • PBMCs peripheral blood mononuclear cells
  • the cells expressing the target antigen in step (2) are prepared by introducing the gene encoding the target antigen into peripheral blood mononuclear cells (PBMCs), according to [1] to [9].
  • the preparation method according to any one item. [10-1]
  • the transposon method is used for the introduction of the target antigen-specific chimeric antigen receptor gene in step (1). Any one of [1] to [10], wherein the cell expressing the target antigen in step (2) is prepared by introducing a gene encoding the target antigen into peripheral blood mononuclear cells (PBMCs).
  • PBMCs peripheral blood mononuclear cells
  • step (a) The preparation method according to any one of [1] to [15], wherein the following step (a) is performed between steps (1) and (2): (A) Non-proliferative cells obtained by stimulating a cell population containing T cells with an anti-CD3 antibody and an anti-CD28 antibody and then performing a treatment for losing proliferative ability, and genetically modified lymphocytes prepared in step (1). A step of mixing lymphocytes and co-culturing while stimulating with anti-CD3 antibody and anti-CD28 antibody.
  • step (b) The preparation method according to any one of [1] to [15], wherein the following step (b) is performed between steps (1) and (2): (B) Non-proliferative PBMCs obtained by treating peripheral blood mononuclear cells (PBMCs) as they are or by stimulating them with anti-CD3 antibody and anti-CD28 antibody and then performing a treatment to lose proliferative ability, and step (1). The step of mixing and co-culturing the genetically modified lymphocytes prepared in.
  • PBMCs peripheral blood mononuclear cells
  • step (c) The preparation method according to any one of [1] to [15], wherein the following step (c) is performed between steps (1) and (2): (C) A cell population containing T cells was stimulated with an anti-CD3 antibody and an anti-CD28 antibody, and then cultured in the presence of the viral peptide antigen and treated to lose the proliferative ability to retain the viral peptide antigen. A step of mixing non-proliferative cells with the transgenic lymphocytes prepared in step (1) and co-culturing them. [19] The preparation method according to [16] or [18], wherein the cell population containing T cells is peripheral blood mononuclear cells (PBMCs).
  • PBMCs peripheral blood mononuclear cells
  • [20] The preparation method according to any one of [16] to [19], wherein the treatment for losing the proliferative ability is irradiation.
  • [21] The preparation method according to any one of [16] to [20], wherein the non-proliferative cells and the genetically modified lymphocytes are derived from the same individual.
  • [22] A genetically modified lymphocyte expressing a chimeric antigen receptor obtained by the preparation method according to any one of [1] to [21].
  • [23] A cell preparation containing a therapeutically effective amount of the genetically modified lymphocyte according to [22].
  • a method for treating cancer which comprises a step of administering a therapeutically effective amount of the genetically modified lymphocyte according to [22] to a cancer patient.
  • Preparation of CAR-T cells by the conventional method (culture method 1).
  • Preparation of CAR-T cells by a novel method (culture method 2).
  • Preparation of CAR-T cells by a novel method (culture method 3).
  • Composition of pIRII-CAR.CD19.28z vector (SEQ ID NO: 1).
  • the CD19CAR gene has a structure sandwiched between a 5'inverted repeat sequence (5'IR) and a 3'inverted repeat sequence (3'IR).
  • CD19CAR has a leader sequence (SEQ ID NO: 2), light chain variable region (VL) (SEQ ID NO: 3), heavy chain variable region (VH) (SEQ ID NO: 4), Fc region (CH2, CH3) (SEQ ID NO: 5), Includes the transmembrane region of CD28 and the intracellular domain (SEQ ID NO: 6) and CD3 ⁇ (SEQ ID NO: 7).
  • Composition of pCMV-pigBac vector SEQ ID NO: 8).
  • the piggyBac transposase gene is located under the control of the CMV earliest promoter (CMV immediate ear1y promoter). Improvement of gene transfer efficiency by a new method (culture method 2).
  • the cells on the 14th day were evaluated by flow cytometry, first cultured for 7 days by the conventional method (culture method 1), then cultured for 7 days by the new method (culture method 2) (upper right), and first 7 After culturing by the conventional method (culture method 1) for 1 day, the gene transfer efficiency was further compared with that cultivated by the conventional method (culture method 1) for 7 days (lower right). Improvement of gene transfer efficiency by a new method (culture method 2). First cultivated by the conventional method (culture method 1) for 7 days, then cultivated by the new method (culture method 2) for 7 days (left), and first cultivated by the conventional method (culture method 1) for 7 days, and then.
  • the proliferation rates of CAR-T cells from the 7th day were compared with those cultured for 7 days by the conventional method (culture method 1) (right).
  • the Fc region CH2, CH3 has been deleted.
  • Improvement of gene transfer efficiency by a new method (culture method 2).
  • the cells on day 7 were evaluated by flow cytometry, and the gene transfer efficiency was compared between the novel method (culture method 2) (upper right) and the conventional method (culture method 1) (lower right). Improvement of gene transfer efficiency by a new method (culture method 2).
  • the number of CAR-T cells was compared between the new method (culture method 2) (left) and the conventional method (culture method 1) (right).
  • CAR cells genetically modified lymphocytes expressing chimeric antigen receptors
  • CAR cells CAR transgenic lymphocytes
  • the preparation method CAR cells (typically CAR-T cells) obtained by the preparation method of the present invention can be used for CAR therapy.
  • the following steps (1) to (3) are performed.
  • various cells for example, T cells in the present specification are human cells.
  • Step of preparing a genetically modified lymphocyte into which a target antigen-specific chimeric antigen receptor gene has been introduced (2) The gene-modified lymphocyte prepared in step (1) is expressed by the chimeric antigen receptor antigen. Steps of culturing in the presence of an anti-idiotype antibody against the recognition region or in the presence of cells expressing the target antigen of the chimeric antigen receptor on which it is expressed (3) Steps of collecting genetically modified lymphocytes after culturing
  • Step (1) is a step of preparing a cell genetically engineered to forcibly express the chimeric antigen receptor gene (CAR gene), and the target antigen-specific CAR gene is introduced into the target cell.
  • CAR gene chimeric antigen receptor gene
  • the CAR gene encodes a chimeric antigen receptor (CAR) that recognizes a specific target antigen.
  • CAR is a structure that contains a target-specific extracellular domain, a transmembrane domain, and an intracellular signal domain for the effector function of immune cells. Hereinafter, each domain will be described.
  • the extracellular domain contains an antigen recognition region and exhibits target-specific binding.
  • the extracellular domain contains a scFv fragment of an antitargeted monoclonal antibody.
  • the monoclonal antibody for example, a rodent (mouse, rat, rabbit, etc.) antibody, a human antibody, a humanized antibody, or the like is used.
  • a humanized monoclonal antibody is an antibody in which the structure of a monoclonal antibody of another animal species (for example, mouse or rat) is similar to that of a human antibody, and only the constant region of the antibody is replaced with that of a human antibody.
  • Human-type CDR-grafted antibody (PT Johons et al., Nature 321,522 (1986) in which the chimeric antibody and the portion other than the CDR (complementarity determining region) existing in the constant region and the variable region are replaced with those of the human antibody. ))including.
  • a method of selecting a human antibody framework (FR) that is highly homologous to a mouse antibody a method of producing a highly homologous humanized antibody, and a mouse CDR to a human antibody in order to enhance the antigen-binding activity of the human CDR transplanted antibody.
  • Further improvements have been made to the method of substituting amino acids in the FR region after transplantation (US Pat. No. 5585089, US Pat. No. 5697361, US Pat. No. 5693762, US Pat. No. 6180370, European Patent No. 451216 , European Patent No. 682040, Patent No. 2828340, etc.), which can also be used to produce humanized antibodies.
  • the scFv fragment is a structure in which the light chain variable region (VL) and heavy chain variable region (VH) of immunoglobulin are linked via a linker, and retains the ability to bind to an antigen.
  • a linker for example, a peptide linker can be used.
  • a peptide linker is a linker composed of peptides in which amino acids are linearly linked.
  • a typical example of a peptide linker is a linker composed of glycine and serine (GGS linker or GS linker).
  • the GGS linker and the amino acids that make up the GS linker, glycine and serine, are small in size and difficult to form higher-order structures in the linker.
  • the length of the linker is not particularly limited. For example, a linker having 5 to 25 amino acid residues can be used. The number of amino acid residues constituting the linker is preferably 8 to 25, more preferably 15 to 20.
  • the target is typically an antigen whose expression is specific to tumor cells.
  • the term "specific expression” as used herein means that significant or remarkable expression is observed as compared with cells other than tumor, and there is no intention of limiting the expression to those having no expression in cells other than tumor.
  • target antigens are CD19 antigen, CD20 antigen, GD2 antigen, CD22 antigen, CD30 antigen, CD33 antigen, CD44variant7 / 8 antigen, CD123 antigen, CEA antigen, Her2 / neu antigen, MUC1 antigen, MUC4 antigen, MUC6 antigen, IL. -13 Receptor-alpha2, immunoglobulin light chain, PSMA antigen, VEGF receptor2, mesothelin antigen, EGFRvIII, EphA2 antigen, IGFR and the like can be mentioned.
  • GM-CSF granulocyte-macricular colony stimulating factor
  • GM-CSF granulocyte-macricular colony stimulating factor
  • Leukemia stem cells, leukemia precursor cells, leukemia cells, etc. of myelogenous tumors are targeted by CAR cells, and myeloproliferative tumors, myelodysplastic / myeloproliferative tumors (CMML, JMML, CML, MDS / MPN-UC) Cells applicable to the prevention and treatment of myelodysplastic syndrome, acute myelogenous leukemia, etc. are prepared.
  • CMML myelodysplastic / myeloproliferative tumors
  • transmembrane domain intervenes between the extracellular domain and the intracellular signal domain.
  • a transmembrane domain such as CD28, CD3 ⁇ , CD8 ⁇ , CD3, CD4 or 4-1BB can be used.
  • a transmembrane domain consisting of an artificially constructed polypeptide may be used.
  • the intracellular signal domain transmits signals necessary for exerting the effector function of immune cells. That is, when the extracellular domain binds to the target antigen, an intracellular signal domain capable of transmitting a signal necessary for activation of immune cells is used.
  • the intracellular signal domain includes a domain for transmitting a signal via the TCR complex (referred to as "first domain” for convenience) and a domain for transmitting a co-stimulation signal (for convenience, "second domain”). Called) is included.
  • first domain an intracellular domain such as Fc ⁇ RI ⁇ can be used in addition to CD3 ⁇ .
  • CD3 ⁇ is used.
  • the intracellular domain of the co-stimulating molecule is used as the second domain. Examples of co-stimulatory molecules include CD28, 4-1BB (CD137), CD2, CD4, CD5, CD134, OX-40 or ICOS.
  • the intracellular domain of CD28 or 4-1BB is adopted.
  • the mode of connection between the first domain and the second domain is not particularly limited, but preferably, the transmembrane domain is preferably transmitted because it is known that the co-stimulation was strongly transmitted when the CD3 ⁇ was connected distally in the past cases. Place the second domain on the side.
  • a plurality of intracellular domains of the same or different species may be linked in a tandem manner to form a first domain. The same applies to the second domain.
  • the first domain and the second domain may be directly linked to each other, or a linker may be interposed between them.
  • a linker for example, a peptide linker can be used.
  • a peptide linker is a linker composed of peptides in which amino acids are linearly linked. The structure, characteristics, etc. of the peptide linker are as described above.
  • a linker composed of only glycine may be used.
  • the length of the linker is not particularly limited. For example, a linker having 2 to 15 amino acid residues can be used.
  • Leader sequences are used to facilitate the transport of CAR onto the cell membrane.
  • the leader sequence of the GM-CSF receptor can be used.
  • the spacer domain is used to promote the binding of CAR to the target antigen.
  • an Fc fragment of human IgG eg, human IgG1, human IgG4 can be used as a spacer domain.
  • a part of the extracellular domain of CD28, a part of the extracellular domain of CD8 ⁇ , and the like can also be used as the spacer domain.
  • a spacer domain can also be provided between the transmembrane domain and the intracellular signal domain.
  • the gene transfer method is roughly classified into a method using a viral vector and a method using a non-viral vector.
  • the former skillfully utilizes the phenomenon that the virus infects cells, and high gene transfer efficiency can be obtained.
  • viral vectors retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated virus vectors, herpesvirus vectors, Sendai viral vectors and the like have been developed.
  • the target gene incorporated into the vector is integrated into the host chromosome, and stable and long-term expression can be expected.
  • Each viral vector can be prepared according to previously reported methods or using commercially available dedicated kits.
  • non-viral vectors include plasmid vectors, liposome vectors, and positively charged liposome vectors (Felgner, PL, Gadek, TR, Holm, M. et al., Proc. Natl. Acad. Sci., 84: 7413-7417. , 1987), YAC vector, BAC vector can be mentioned.
  • transposon method is one of the non-viral gene transfer methods.
  • Transposon is a general term for short gene sequences that cause gene translocations that have been conserved during evolution.
  • a pair of gene enzyme (transposase) and its specific recognition sequence causes gene translocation.
  • the transposon method for example, the piggyBac transposon method can be used.
  • the PiggyBac transposon method utilizes transposons isolated from insects (Fraser MJ et al., Insect Mol Biol. 1996 May; 5 (2): 141-51 .; Wilson MH et al., Mol Ther. .
  • the transposon method applicable to the present invention is not limited to the one using piggyBac, for example, Sleeping Beauty (Ivics Z, hackett PB, Plasterk RH, Izsvak Z (1997) Cell 91: 501-510.), Frog Prince (Miskey C, Izsvak Z, Plasterk RH, Ivics Z (2003) Nucleic Acids Res 31: 6873-6881.), Tol1 (Koga A, Inagaki H, Bessho Y, Hori H. 249 (4): 400-5 .; Koga A, Shimada A, Kuroki T, Hori H, Kusumi J, Kyono-Hamaguchi Y, Hamaguchi S. J Hum Genet.
  • the CAR gene transfer operation by the transposon method may be performed by a conventional method, and past literature (for example, for the piggyBac transposon method, Nakazawa Y, et al., J Immunother 32: 826-836, 2009, Nakazawa Y et al., J Immunother 6: 3-10, 2013, Saha S, Nakazawa Y, Huye LE, Doherty JE, Galvan DL, Rooney CM, Wilson MH. J Vis Exp. 2012 Nov 5; (69): e4235, Saito S, Nakazawa Y, Sueki A, et al. Anti-leukemic potential of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromasome-positive acute lymphoblastic leukemia. Cytotherapy. 2014; 16: 1257-69.) Is helpful.
  • the piggyBac transposon method is adopted.
  • a vector carrying a gene encoding the piggyBac transposase (transposase plasmid) and a desired nucleic acid construct (CAR expression cassette and / or siRNA expression cassette) are sandwiched between piggyBac reverse repeat sequences.
  • Vectors having a structure (transposon plasmid) are prepared, and these vectors are introduced (transfected) into target cells.
  • various methods such as electroporation, nucleofection, lipofection, and calcium phosphate method can be used.
  • a poly A addition signal sequence is placed downstream of the CAR gene. Transcription is terminated by the use of the poly A addition signal sequence.
  • a poly A addition signal sequence a poly A addition sequence of SV40, a poly A addition sequence of a bovine growth hormone gene, or the like can be used.
  • the transposon plasmid may include a detection gene (reporter gene, cell or tissue-specific gene, selectable marker gene, etc.), enhancer sequence, WRPE sequence, and the like.
  • the detection gene is used for determining the success or failure and efficiency of the introduction of the expression cassette, detecting the expression of the CAR gene or determining the expression efficiency, selecting and sorting the cells expressing the CAR gene, and the like.
  • the expression efficiency can be improved by using the enhancer sequence.
  • the genes for detection include the neo gene that imparts resistance to neomycin, the npt gene that imparts resistance to kanamycin, etc. (Herrera Estrella, EMBO J.
  • npt II gene (Messing & Vierra. Gene 1). 9: 259-268 (1982)), hph gene conferring resistance to neomycin (Blochinger & Digglmann, Mol Cell Bio 4: 2929-2931), dhfr gene conferring resistance to metatrexate (Bourouis et al. , EMBO J.2 (7)), etc. (marker gene), luciferase gene (Giacomin, P1. Sci. 116 (1996), 59-72; Scikantha, J. Bact.
  • GUS ⁇ -Glucronidase
  • genes for fluorescent proteins such as GFP (Gerdes, FEBS Lett. 389 (1996), 44-47) and their variants (EGFP, d2EGFP, etc.
  • GFP Gerdes, FEBS Lett. 389 (1996), 44-47) and their variants (EGFP, d2EGFP, etc.
  • intracellular domains Genes such as the missing epithelial growth factor receptor (EGFR) gene can be used.
  • the detection gene is linked to the CAR gene via, for example, a bicistronic control sequence (eg, ribosome internal recognition sequence (IRES)) or a sequence encoding a self-cleaving peptide.
  • a bicistronic control sequence eg, ribosome internal recognition sequence (IRES)
  • IRS ribosome internal recognition sequence
  • An example of a self-cleaving peptide is, but is not limited to, a 2A peptide (T2A) derived from Thosea signa virus.
  • E2A horse rhinitis A virus
  • P2A porcine teschovirus
  • Target cells include CD4-positive CD8-negative T cells, CD4-negative CD8-positive T cells, T cells prepared from iPS cells, ⁇ -T cells, ⁇ -T cells, NK cells, and NKT cells. Can be mentioned. Various cell populations can be used as long as they contain lymphocytes or progenitor cells as described above.
  • Peripheral blood mononuclear cells (PBMCs) collected from peripheral blood are one of the preferred target cells. That is, in a preferred embodiment, a gene transfer operation is performed on PBMCs, which are a cell population containing T cells or progenitor cells.
  • PBMCs may be prepared by a conventional method.
  • PBMCs For the method of preparing PBMCs, refer to, for example, Saha S, Nakazawa Y, Huye LE, Doherty JE, Galvan DL, Rooney CM, Wilson MH. J Vis Exp. 2012 Nov 5; (69): e4235. it can.
  • Step (2) The genetically modified lymphocytes (CAR cells) prepared in step (1) are subjected to culturing under specific conditions (step (2)).
  • the genetically modified lymphocyte prepared in step (1) is cultured in the presence of an anti-iditope antibody against the antigen recognition region of the chimeric antigen receptor on which it is expressed.
  • the genetically modified lymphocyte prepared in step (1) is cultured in the presence of cells expressing the target antigen of the chimeric antigen receptor on which it is expressed (target antigen expressing cells).
  • the target CAR cells (that is, those into which the target antigen-specific chimeric antigen receptor gene has been introduced) are specifically stimulated by culturing in the presence of anti-iditope antibody or target antigen-expressing cells. , To improve the proliferation rate.
  • the anti-iditope antibody used in the first aspect may be prepared by using an immunological method, a phage display method, a ribosome display method, or the like. Specifically, it can be produced according to a known method such as the method described in PLoS One. 2013; 8 (3): e57838. Further, an anti-iditope antibody may be prepared by using a contract service (for example, GenScript, Creative Biolabs, Immuno-Biological Laboratories, Inc., GeneFrontier Corp.). The anti-iditope antibody may be either a polyclonal antibody or a monoclonal antibody.
  • the anti-iditope antibody is an antibody that recognizes the antigen recognition region (variable domain) of an antibody molecule and binds to an epitope (idiotope) in a specific idiotype.
  • the anti-iditope antibody includes an anti-iditope antibody against CD19CAR, an anti-iditopes antibody against GD2CAR, an anti-iditopes antibody against CD22CAR, an anti-iditopes antibody against BCMACAR, and an anti-iditopes antibody against CD5CAR.
  • Examples thereof include an anti-iditope antibody against CD123CAR and an anti-iditopes antibody against HER2CAR.
  • Preferred examples thereof include an anti-iditope antibody against CD19CAR and an anti-iditopes antibody against GD2CAR.
  • the anti-iditope antibody may contain a constant region of immunoglobulin or may not contain a constant region of immunoglobulin.
  • the constant region of the heavy chain (CH1, CH2, and CH3) and the constant region of the light chain (CL) may be all included, and any one or more of these may be included. May include a combination of.
  • Specific examples of anti-iditope antibodies include immunoglobulin structure, Fab structure, F (ab') 2 structure, minibody structure, scFv-Fc structure, Fv structure, scFv structure, and diabody structure. , Triabody structure, tetrabody structure and the like.
  • anti-iditope antibodies also include low molecular weight antibodies such as Nanobodies and monobodies.
  • CAR cells and anti-iditope antibody By culturing in the presence of anti-iditope antibody, CAR cells and anti-iditope antibody can be brought into contact with each other.
  • an anti-iditopes antibody is immobilized on the culture surface of a culture vessel, the contact state can be formed during the culture.
  • the substrate used for solid phase formation include a substrate containing plastic such as polystyrene, glass, nitrocellulose and the like as a main component.
  • solid phase is meant that the anti-iditopes antibody is immobilized by binding directly or indirectly to the substrate. Fixation of the anti-iditopes antibody to the substrate can be performed according to or according to a conventional method.
  • fixation examples thereof include fixation via a covalent bond, fixation via a bond between avidin or streptavidin and biotin, and fixation by physical adsorption. Further, by adding an anti-iditope antibody (beaded antibody) bound to beads (for example, magnetic beads) to the culture medium, it is possible to form a state in which CAR cells and the anti-iditope antibody can be contacted.
  • the material of the beads is not particularly limited, and for example, metal particles such as gold, silver, copper, iron, aluminum, nickel, manganese, titanium, and oxides thereof; resin particles such as polystyrene and latex; silica particles and the like. Can be mentioned.
  • the shape of the bead is not particularly limited, and examples thereof include a sphere, a rectangular parallelepiped, a cube, a triangular pyramid, and the like, or a shape close to these.
  • the bead preferably has a substance on its surface to make the binding of the anti-iditope antibody easier and / or stronger. Examples of such substances include substances having a reactive group such as an epoxy group, an amino group, a carboxy group and an azide group; and substances having an affinity for other molecules such as avidin, protein A and protein B. Can be mentioned.
  • the target antigen-expressing cell used in the second aspect is not particularly limited as long as it is a cell in which the antigen (particularly the CAR recognition portion) is exposed on the cell surface.
  • it can be prepared by introducing a gene encoding a target antigen into peripheral blood mononuclear cells (PBMCs).
  • PBMCs peripheral blood mononuclear cells
  • a specific cell population for example, T cells, B cells, NK cells, dendritic cells, or a combination of two or more of these
  • a gene encoding an antigen may be introduced.
  • a cell such as K562 can also be used as a cell into which a gene encoding a target antigen is introduced.
  • the expression of the target antigen may be transient or constant.
  • various vectors such as a plasmid may be used. More specifically, gene transfer can be carried out in the same manner as, for example, the above-mentioned CAR gene transfer.
  • the origin of the genetically modified lymphocyte (CAR cell) prepared in step (1) and the target antigen-expressing cell are the same.
  • CAR cells and target antigen-expressing cells are prepared using cells isolated from the same individual. In this way, it is possible to avoid the addition of unintended stimuli to CAR cells, the problem of immune rejection, infectious diseases, and the like.
  • the individual from which the CAR cells and the target antigen-expressing cells are derived is a patient (recipient) (autologous transplantation) or another person (allogeneic transplantation) who receives the CAR cells obtained by the preparation method of the present invention. is there.
  • the latter (ie, in the case of allogeneic transplantation) is applied to patients who have difficulty in preparing the cells necessary for the preparation of CAR cells, for example, when there are few lymphocytes in the blood or the activity of lymphocytes is low. It can be said that it is suitable for preparing.
  • Step (2) may be performed after 48 hours, more preferably 16 to 24 hours) have elapsed.
  • T cell growth factors include IL-2, IL-7 and IL-15, of which IL-15 is particularly useful.
  • a culture solution to which IL-7 is added in addition to IL-15 is used.
  • the amount of IL-15 added is, for example, 5 ng / ml to 10 ng / ml.
  • T cell growth factors such as IL-15 and IL-7 can be prepared according to a conventional method. In addition, a commercially available product can also be used. Although the use of T cell growth factors in non-human animal species is not excluded, T cell growth factors are usually derived from humans (may be recombinants). Growth factors such as human IL-15 and human IL-7 can be easily obtained (for example, provided by Miltenyi Biotec, R & D Systems, etc.).
  • a medium supplemented with serum (human serum, fetal bovine serum, etc.) may be used, but by adopting a serum-free medium, it is highly safe for clinical application and the culture efficiency due to the difference between serum lots is high. It is possible to prepare cells that have the advantage of being less likely to make a difference.
  • Specific examples of serum-free media for lymphocytes are TexMACS TM (Miltenyi Biotec) and AIM V® (Thermo Fisher Scientific).
  • a medium to which autologous serum (recipient's serum) is added may be used.
  • a medium suitable for lymphocyte culture may be used as the basal medium, and specific examples thereof are TexMACS TM and AIM V (registered trademark) described above.
  • Other culture conditions may be any one suitable for the survival and proliferation of lymphocytes, and general ones may be adopted.
  • the cells may be cultured in a CO 2 incubator (CO 2 concentration 5%) set at 37 ° C.
  • the culture period of step (2) is, for example, 1 to 14 days, preferably 1 to 7 days, and more preferably 2 to 7 days. If the culturing period is too short, a sufficient effect cannot be expected, and if the culturing period is too long, the cell activity (life force) may decrease.
  • the transposon method is used to introduce the target antigen-specific chimeric antigen receptor gene in step (1), and the cells expressing the target antigen in step (2) encode the target antigen. It is prepared by introducing the gene into peripheral blood mononuclear cells (PBMCs).
  • PBMCs peripheral blood mononuclear cells
  • the piggyBac transposon method is used to introduce the target antigen-specific chimeric antigen receptor gene in step (1), and the cells expressing the target antigen in step (2) use the target antigen. It is prepared by introducing the encoding gene into peripheral blood mononuclear cells (PBMCs).
  • Step (3) the genetically modified lymphocytes (CAR cells) after culturing are collected.
  • the collection operation may be performed by a conventional method. For example, it is collected by pipetting, centrifugation, or the like.
  • a step of culturing the cultured CAR cells in the presence of T cell growth factor is performed between steps (2) and (3). This step enables efficient expansion culture and also has the advantage of increasing cell viability.
  • IL-15, IL-7, etc. can be used as T cell growth factors.
  • the cells are cultured in a medium supplemented with IL-15 and IL-7 in the same manner as in step (2).
  • the culture period is, for example, 1 to 21 days, preferably 5 to 18 days, and more preferably 10 to 14 days. If the culture period is too short, a sufficient increase in the number of cells cannot be expected, and if the culture period is too long, there is a risk of a decrease in cell activity (life force), cell exhaustion / fatigue, and the like. It may be subcultured in the middle of culturing.
  • the medium is changed as necessary during the culture. For example, replace about 1/3 to 2/3 of the culture medium with a new medium once every 3 days.
  • step (1) and step (2) the following step (a) is performed.
  • Non-proliferative cells obtained by stimulating a cell population containing T cells with an anti-CD3 antibody and an anti-CD28 antibody and then performing a treatment for losing proliferative ability, and genetically modified lymphocytes prepared in step (1). Steps of mixing lymphocytes and co-culturing while stimulating with anti-CD3 antibody and anti-CD28 antibody
  • step (a) non-proliferative cells used for protection of CAR cells (CAR cells used in step (2)) after the transfer operation of the target antigen-specific chimeric antigen receptor gene are prepared, and in step (1). It is used for co-culture with the prepared CAR cells.
  • PBMCs peripheral blood mononuclear cells collected from peripheral blood are preferably used. It is also possible to use PBMCs purified to increase the T cell content, mononuclear cells collected from peripheral blood by feresis, or the like as the "cell population containing T cells" here.
  • T cells in the cell population can be stimulated with anti-CD3 antibody and anti-CD28 antibody.
  • Anti-CD3 antibody for example, the trade name CD3pure antibody provided by Miltenyi Biotec
  • anti-CD28 antibody for example, the trade name CD28pure antibody provided by Miltenyi Biotec can be used
  • step (a) it is also possible to perform the stimulation in step (a) using magnetic beads coated with anti-CD3 antibody and anti-CD28 antibody (for example, Dynabeads T-Activator CD3 / CD28 provided by VERITAS). It is preferable to use an "OKT3" clone as the anti-CD3 antibody.
  • anti-CD3 antibody and anti-CD28 antibody for example, Dynabeads T-Activator CD3 / CD28 provided by VERITAS. It is preferable to use an "OKT3" clone as the anti-CD3 antibody.
  • Cells stimulated with anti-CD3 antibody and anti-CD28 antibody are subjected to a treatment to lose proliferative ability, but before that, it is advisable to culture in the presence of T cell growth factor.
  • This culture enhances the activity of the cells after the stimulation treatment.
  • the culture period here is, for example, 1 to 10 days, preferably 2 to 7 days, and more preferably 3 to 4 days. If the culture period is too short, sufficient activation cannot be expected, and if the culture period is too long, co-stimulatory molecules may be attenuated.
  • the cultured cells may be cryopreserved once. In this case, the cells may be thawed at the time of use, stimulated again with anti-CD3 antibody and CD28 antibody (conditions conform to the above), and then subjected to "treatment to lose proliferative ability".
  • Activated T cells that have lost their proliferative ability can be obtained by undergoing the "treatment that causes them to lose their proliferative ability".
  • the treatment that causes the loss of proliferative capacity is typically irradiation, but agents may also be used.
  • An example of irradiation conditions is a treatment using gamma rays at an intensity of 25 Gy to 50 Gy for 15 to 30 minutes.
  • the non-proliferative cells prepared as described above and the CAR cells prepared in step (1) are mixed and co-cultured while stimulating with anti-CD3 antibody and anti-CD28 antibody.
  • stimulation by co-stimulatory molecules by non-proliferative cells and stimulation by anti-CD3 antibody and anti-CD28 antibody are added, CAR cells are activated, and their survival and proliferation are promoted.
  • This co-culture is preferably carried out immediately after the CAR gene transfer operation when preparing CAR cells. For example, co-culture is started immediately after the CAR gene transfer operation or within 1 day.
  • the co-culture (that is, step (a)) and the above step (2) may be performed at the same time, in which case the start time of step (2) is the same as the start time of step (a) (for example). , Immediately after the CAR gene transfer operation or within 1 day).
  • the ratio of the number of non-proliferative cells to the number of genetically modified lymphocytes (CAR cells) used for co-culture is not particularly limited, but is, for example, 0.025 to 0.5. And.
  • T cell growth factors include IL-2, IL-7 and IL-15, of which IL-15 is particularly useful.
  • IL-15 a culture solution to which IL-7 is added in addition to IL-15 is used.
  • the amount of IL-15 added is, for example, 5 ng / ml to 10 ng / ml.
  • the amount of IL-7 added is, for example, 5 ng / ml to 10 ng / ml.
  • a medium supplemented with serum (human serum, fetal bovine serum, etc.) may be used, but by adopting a serum-free medium, it is highly safe for clinical application and the culture efficiency due to the difference between serum lots is high. It is possible to prepare cells that have the advantage of being less likely to make a difference.
  • Specific examples of serum-free media for lymphocytes are TexMACS TM (Miltenyi Biotec) and AIM V® (Thermo Fisher Scientific).
  • a medium to which autologous serum (recipient's serum) is added may be used.
  • a medium suitable for lymphocyte culture may be used as the basal medium, and specific examples thereof are TexMACS TM and AIM V (registered trademark) described above.
  • Other culture conditions may be any one suitable for the survival and proliferation of lymphocytes, and general ones may be adopted.
  • the cells may be cultured in a CO 2 incubator (CO 2 concentration 5%) set at 37 ° C.
  • the co-culture period is, for example, 1 to 10 days, preferably 1 to 7 days, and more preferably 2 to 4 days. If the culturing period is too short, a sufficient effect cannot be expected, and if the culturing period is too long, the cell activity (life force) may decrease.
  • step (b) Protection of cells after CAR gene transfer operation by co-culture with non-proliferative PBMCs
  • step (b) is performed between steps (1) and (2).
  • step (B) Non-proliferative PBMCs obtained by stimulating PBMCs as they are or with anti-CD3 antibody and anti-CD28 antibody and then performing a treatment to lose proliferative ability, and genetically modified lymphocytes prepared in step (1). Steps to mix and co-culture
  • step (b) non-proliferative PBMCs used for protection of CAR cells (CAR cells used in step (2)) after the transfer operation of the target antigen-specific chimeric antigen receptor gene are prepared, and in step (1). It is used for co-culture with the prepared CAR cells.
  • the method for stimulating PBMCs with anti-CD3 antibody and anti-CD28 antibody is as described in 1-2 above. Is similar to.
  • the treatment for losing the proliferative ability, and prior to that, culturing in the presence of T cell growth factor and the method thereof are also described in 1-2. Is similar to.
  • "as is PBMCs" means that PBMCs are not stimulated by anti-CD3 antibody and anti-CD28 antibody.
  • the non-proliferative PBMCs prepared as described above are mixed with the genetically modified lymphocytes (CAR cells) prepared in step (1) and co-cultured.
  • Co-culture may be performed while stimulating with an anti-CD3 antibody and an anti-CD28 antibody.
  • This co-culture is preferably carried out immediately after the CAR gene transfer operation when preparing CAR cells. For example, co-culture is started immediately after the CAR gene transfer operation or within 1 day.
  • the co-culture (that is, step (b)) and the above step (2) may be performed at the same time, in which case the start time of step (2) is the same as the start time of step (b) (for example). , Immediately after the CAR gene transfer operation or within 1 day).
  • the ratio of the number of non-proliferative PBMCs used for co-culture to the number of genetically modified lymphocytes (CAR cells) is not particularly limited, but is, for example, 0.025 to 0.5. , Preferably 0.05 to 1.0.
  • T cell growth factors include IL-2, IL-7 and IL-15, of which IL-15 is particularly useful.
  • a culture solution to which IL-7 is added in addition to IL-15 is used.
  • the amount of IL-15 added is, for example, 5 ng / ml to 10 ng / ml.
  • the amount of IL-7 added is, for example, 5 ng / ml to 10 ng / ml.
  • Conditions not mentioned are described in 1-2. Is the same as in the case of the above aspect.
  • Non-proliferative PBMCs may be added in the middle of co-culture (for example, 3 to 11 days after the start of co-culture, preferably 5 to 9 days, and more preferably 7 days).
  • the cells after co-culture may be collected, mixed with other non-proliferative PBMCs, and then cultured again. These operations may be repeated twice or more. In this way, if stimulation or activation using non-proliferative PBMCs is performed a plurality of times, it is expected that the induction rate of CAR cells will be improved and the number of CAR cells will be increased.
  • those prepared again, or those prepared by culturing a part of the cells prepared at the beginning or those stored in a cryopreservation can be used as the non-proliferative PBMCs here.
  • non-proliferative PBMCs are prepared using a part of PBMCs isolated from peripheral blood obtained by one blood sampling and CAR cells are prepared from the other part, the present invention can be carried out.
  • the number of blood samplings involved can be reduced, which is an extremely great advantage in clinical application.
  • non-proliferative PBMCs If it is used as additional non-proliferative PBMCs, then the three required cells, namely CAR cells, non-proliferative PBMCs used for co-culture with the cells, in the middle of co-culture Since non-proliferative PBMCs for addition can be prepared by a single blood collection, the burden on the patient in the treatment using the CAR cells obtained in the present invention is greatly reduced.
  • virus-specific chimeric antigen receptor gene-modified lymphocytes by co-culture with T cells carrying a virus peptide
  • virus-specific chimeric antigen receptor gene-modified lymphocytes (virus-specific). CAR cells) are prepared.
  • Virus-specific CAR cells can be expected to improve internal persistence by stimulation from viral T cell receptors when used for autologous transplantation, and further reduce allogeneic immune response (GVHD) when used for allogeneic transplantation. This has important advantages in clinical application, such as the possibility of producing CAR cells from a transplant donor and the possibility of formulating CAR cells from a third-party donor.
  • virus-specific CAR cells have been reported to persist in the body for longer periods of time (Pule MA, et al. Nat Med. 2008 Nov; 14 (11): 1264-70.).
  • CTL cytotoxic T cells
  • step (c) is performed to prepare virus-specific CAR cells. Matters not mentioned (for example, method for preparing a cell population containing T cells, basic operation for stimulation with anti-CD3 antibody and anti-CD28 antibody, method for processing to lose proliferative ability, basic operation for co-culture, etc. ) Is described in 1-2. Since it is the same as the aspect of the above, duplicate explanations are omitted and the corresponding explanations are used.
  • C A cell population containing T cells was stimulated with an anti-CD3 antibody and an anti-CD28 antibody, and then cultured in the presence of the viral peptide antigen and treated to lose the proliferative ability to retain the viral peptide antigen. The step of mixing non-proliferative cells with the genetically modified lymphocytes prepared in step (1) and co-culturing them.
  • step (c) first, a cell population containing T cells is stimulated with an anti-CD3 antibody and an anti-CD28 antibody to obtain activated T cells. Then, the cells are cultured in the presence of the viral peptide antigen and treated to lose their proliferative ability. As a result, non-proliferative "activated T cells holding a viral peptide antigen on the cell surface" (hereinafter referred to as "viral peptide-retaining non-proliferative cells”) are obtained.
  • the order of culturing in the presence of the viral peptide antigen and the treatment for losing the proliferative ability is not particularly limited.
  • the growth ability may be lost after culturing in the presence of the virus peptide antigen, or the culture may be performed in the presence of the virus peptide antigen after the loss of the growth ability.
  • the former order is adopted because of the expectation that the uptake of the viral peptide antigen will be better before the loss of proliferative capacity.
  • a medium to which the viral peptide antigen has been added may be used.
  • the viral peptide antigen may be added to the medium during culturing.
  • the concentration of the viral peptide antigen added is, for example, 0.5 ⁇ g / ml to 1 ⁇ g / ml.
  • the culture period is, for example, 10 minutes to 5 hours, preferably 20 minutes to 3 hours.
  • viral peptide antigen refers to an epitope peptide or a long peptide containing an epitope capable of inducing cytotoxic T cells (CTL) specific to a specific virus.
  • the viral peptide antigen is not limited to these, but is, for example, an adenovirus (AdV) antigen peptide (see, for example, WO2007015540 A1) and a cytomegalovirus (CMV) antigen peptide (for example, JP-A-2002).
  • AdV adenovirus
  • CMV cytomegalovirus
  • Epstein-Barr virus (EBV) antigen peptide for example, WO 2007049737 A1, Japanese Patent Application No. 2011-177487, Japanese Patent Application Laid-Open No. (See 2006-188513), etc.
  • the viral peptide antigen can be prepared by a conventional method (for example, liquid phase synthesis method, solid phase synthesis method) based on the sequence information.
  • some viral peptide antigens are commercially available (for example, provided by Medical & Biological Laboratories, Ltd., Takara Bio, Miltenyi Biotec, etc.).
  • antigen peptide mixture usually two or more types of antigen peptides (antigen peptide mixture) are used.
  • antigen peptide mixture usually two or more types of antigen peptides (antigen peptide mixture) are used.
  • AdV antigen peptide mixture CMV antigen peptide mixture or EBV antigen peptide mixture, or a combination of two or more of these antigen peptide mixture (for example, AdV antigen peptide mixture, CMV antigen peptide mixture and EBV antigen peptide mixture).
  • AdV antigen peptide mixture for example, AdV antigen peptide mixture, CMV antigen peptide mixture and EBV antigen peptide mixture.
  • a plurality of activated T cells having different targets can be obtained, and the virus-specific CAR cells obtained by the preparation method of the present invention are effective therapeutic targets ( We can expect an increase in the number of patients (improvement of coverage).
  • the use of the virus-specific CAR cells obtained by the preparation method of the present invention specifically, the disease to be treated and the pathological condition of the patient should be considered. Good.
  • the antigen-peptide mixture of EBV virus may be used alone or in combination with an antigen-peptide mixture of other viruses.
  • AdV antigen-peptide mixture, CMV antigen-peptide mixture, and EBV antigen-peptide mixture are also commercially available (for example, PepTivator (registered trademark) AdV5 Hexon, PepTivator (registered trademark) CMV pp65, PepTivator (for example, provided by Milteny Biotech).
  • EBV EBNA-1 Registered trademarks
  • PepTivator registered trademark
  • EBV BZLF1 PepMix TM Collection HCMV provided by JPT Peptide Technologies
  • PepMix TM EBV (EBNA1), etc.) can be easily obtained.
  • the viral peptide-retaining non-proliferative cells prepared as described above and the genetically modified lymphocytes (CAR cells) prepared in step (1) are mixed and co-cultured.
  • stimulation via a co-stimulating molecule and a virus antigen peptide by a virus peptide-carrying non-proliferative cell is applied, and virus antigen-specific genetically modified lymphocytes are activated and their survival and proliferation are promoted.
  • this co-culture is used for CAR genes in preparing CAR cells. It is preferable to carry out immediately after the introduction operation.
  • co-culture is started immediately after the CAR gene transfer operation or within 1 day.
  • the co-culture (that is, step (c)) and the above step (2) may be performed at the same time, in which case the start time of step (2) is the same as the start time of step (c) (for example).
  • the start time of step (2) is the same as the start time of step (c) (for example).
  • the ratio of the number of viral peptide-carrying non-proliferative cells used for co-culture to the number of genetically modified lymphocytes (CAR cells) is not particularly limited. For example, 0.025 to 0.5, preferably 0.05 to 1.0.
  • this step is to stimulate with anti-CD3 antibody and anti-CD28 antibody for reasons such as selectively proliferating virus-specific CAR cells, avoiding strong stimulation and preventing T cell exhaustion / fatigue. Do not add.
  • a culture medium to which a T cell growth factor has been added during co-culture examples include IL-2, IL-7 and IL-15, of which IL-15 is particularly useful.
  • IL-15 a culture solution to which IL-7 is added in addition to IL-15 is used.
  • the amount of IL-15 added is, for example, 5 ng / ml to 10 ng / ml.
  • the amount of IL-7 added is, for example, 5 ng / ml to 10 ng / ml.
  • Conditions not mentioned are described in 1-2. Is the same as in the case of the above aspect.
  • Viral peptide-carrying non-proliferative cells may be added during co-culture. Alternatively, the cells after co-culture may be collected, mixed with another virus peptide-carrying non-proliferative cell, and then co-cultured again. These operations may be repeated twice or more. As described above, if the activation without stimulation using the virus peptide-retaining non-proliferative cells is performed a plurality of times, the induction rate of the virus-specific CAR cells can be improved and the number of virus-specific CAR cells can be expected to increase. In addition, a cell prepared again or a cell in which a part of the cell prepared at the beginning is preserved can be used as "another viral peptide-carrying non-proliferative cell" here.
  • the co-culture period is, for example, 1 to 21 days, preferably 5 to 18 days, and more preferably 10 to 14 days. If the culturing period is too short, a sufficient effect cannot be expected, and if the culturing period is too long, there is a risk of a decrease in cell activity (life force), cell exhaustion / fatigue, and the like.
  • the genetically modified lymphocytes (CAR cells) prepared in step (1) Prior to co-culturing with viral peptide-carrying non-proliferative cells, the genetically modified lymphocytes (CAR cells) prepared in step (1) are co-cultured with viral peptide-carrying non-proliferative peripheral blood mononuclear cells (PBMCs). It may be.
  • the period of co-culture here is, for example, 1 to 21 days, preferably 5 to 18 days, and more preferably 10 to 14 days.
  • the cells obtained by co-culturing the genetically modified lymphocytes (CAR cells) prepared in step (1) and the viral peptide-carrying non-proliferative PBMCs (co-culture in the first step) are obtained by the above method.
  • the viral peptide-retaining non-proliferative PBMCs here can be prepared by subjecting the PBMCs to a culture in the presence of a viral peptide antigen and a treatment for losing the ability to proliferate. Specifically, for example, PBMCs isolated from peripheral blood are radiation-treated and then cultured in the presence of a viral peptide antigen to obtain viral peptide-retaining non-proliferative PBMCs.
  • the present invention if it is decided to prepare viral peptide-retaining non-proliferative PBMCs using a part of PBMCs isolated from peripheral blood obtained by one blood sampling and to prepare CAR cells from the other part, the present invention. It is possible to reduce the number of blood samplings associated with the implementation of the above, which is an extremely great advantage in clinical application.
  • the remaining PBMCs are used to prepare viral peptide-retaining non-proliferative cells (cells used for the second stage co-culture), or the viral peptide-retaining non-proliferative PBMCs prepared using a part of PBMCs.
  • the necessary three types Cells that is, CAR cells, viral peptide-retaining non-proliferative PBMCs used for co-culture with the cells (first-stage co-culture), and viral peptide-retaining non-proliferative cells used for second-stage co-culture. Since it can be prepared by collecting blood once, the burden on the patient in the treatment using the CAR cells obtained in the present invention is greatly reduced.
  • CAR cells Gene-modified lymphocytes expressing chimeric antigen receptor and their uses Further aspects of the present invention are the genetically modified lymphocytes expressing chimeric antigen receptor obtained by the preparation method of the present invention (hereinafter, “the present invention”. "CAR cells") and their uses.
  • the CAR cells of the present invention can be used for the treatment, prevention or amelioration of various diseases (hereinafter referred to as "target diseases") for which CAR therapy is considered to be effective.
  • target diseases various diseases
  • the representative of the target disease is cancer, but it is not limited to this.
  • target diseases include various B-cell lymphomas (follicle malignant lymphoma, diffuse malignant lymphoma, mantle cell lymphoma, MALT lymphoma, intravascular B-cell lymphoma, CD20-positive hodgkin lymphoma, etc.), myeloproliferative neoplasm, bone marrow.
  • B-cell lymphomas follicle malignant lymphoma, diffuse malignant lymphoma, mantle cell lymphoma, MALT lymphoma, intravascular B-cell lymphoma, CD20-positive hodgkin lymphoma, etc.
  • myeloproliferative neoplasm myeloproliferative neoplasm
  • bone marrow myeloproliferative neoplasm
  • CMML Hypoplastic / myeloproliferative neoplasms
  • JMML Hypoplastic / myeloproliferative neoplasms
  • CML Hypoplastic / myeloproliferative neoplasms
  • MDS Hypoplastic / myeloproliferative neoplasms
  • myelodysplastic syndrome acute myeloproliferative leukemia, neuroblastoma, brain tumor, Ewing sarcoma, osteosarcoma, retinoblastoma, small lung Celloma, melanoma, ovarian cancer, horizontal print myeloma, kidney cancer, pancreatic cancer, malignant mesoderma, prostate cancer, etc.
  • Treatment includes alleviating (mitigating) the symptoms characteristic of the target disease or associated symptoms, preventing or delaying the exacerbation of the symptoms, and the like.
  • Prevention means preventing or delaying the onset / delay of a disease (disorder) or its symptoms, or reducing the risk of onset / onset.
  • improvement means that the disease (disorder) or its symptoms are alleviated (mild), improved, ameliorated, or cured (including partial cure).
  • the CAR cells of the present invention can also be provided in the form of a cell preparation.
  • the cell preparation of the present invention contains a therapeutically effective amount of the CAR cells of the present invention. For example, it contains 10 4 to 10 10 cells for a single dose.
  • Various components such as dimethylsulfoxide (DMSO) and serum albumin for the purpose of protecting cells, antibiotics for the purpose of preventing bacterial contamination, and various components (vitamins) for the purpose of activating, proliferating or inducing differentiation of cells.
  • DMSO dimethylsulfoxide
  • serum albumin for the purpose of protecting cells
  • antibiotics for the purpose of preventing bacterial contamination
  • various components for the purpose of activating, proliferating or inducing differentiation of cells.
  • Cytokines, growth factors, steroids, etc. may be contained in the cell preparation.
  • the administration route of the CAR cell or cell preparation of the present invention is not particularly limited. For example, it is administered by intravenous injection, intraarterial injection, intraportal injection, intradermal injection, subcutaneous injection, intramuscular injection, or intraperitoneal injection. Topical administration may be used instead of systemic administration.
  • Topical administration may be used instead of systemic administration.
  • local administration direct injection into a target tissue / organ / organ can be exemplified.
  • the administration schedule may be prepared in consideration of the gender, age, body weight, pathological condition, etc. of the subject (patient). In addition to a single dose, multiple doses may be administered continuously or periodically.
  • PBMCs mononuclear cells
  • PBMCs mononuclear cells
  • 5 ⁇ g of a plasmid vector expressing the CAR target antigen is introduced by electroporation (nucleofection), and culture is started in an incubator.
  • Day 1 After irradiation, it is used as a feeder cell.
  • Day 1 Stimulate with anti-CD3 antibody / anti-CD28 antibody coated plate.
  • Day 4 Transfer cells to G-Rex 10 and incubate with TexMACS TM supplemented with IL-7 10 ng / ml and IL 15 5 ng / ml.
  • Day 7 Replace half of the culture with TexMACS TM with IL-7 10 ng / ml and IL 15 5 ng / ml.
  • Day 10 Replace half of the culture with IL-7 10 ng / ml and IL 15 5 ng / ml TexMACS TM.
  • Day 14 The culture is finished.
  • Day 1 Stimulate with an anti-iditope antibody coated plate.
  • Day 4 Transfer cells to G-Rex 10 and incubate with TexMACS TM supplemented with IL-7 10 ng / ml and IL 15 5 ng / ml.
  • Day 7 Replace half of the culture with TexMACS TM with IL-7 10 ng / ml and IL 15 5 ng / ml.
  • Day 10 Replace half of the culture with IL-7 10 ng / ml and IL 15 5 ng / ml TexMACS TM.
  • Day 14 The culture is finished.
  • PBMCs target antigen-expressing cells
  • Day 0 Mononuclear cells were isolated from peripheral blood, and 5 ng each of pIRII-CAR.CD19.28z vector (Fig. 4) and pCMV-pigBac vector (Fig. 5) were added to 1x10 7 mononuclear cells. Then, the gene is introduced by electroporation (nucleofection). Then, the cells are floated on TexMACS TM supplemented with IL-7 10 ng / ml and IL15 5 ng / ml, and culture is started in a 37 ° C.
  • Day 1 Stimulate with target antigen gene-introduced PBMCs (feeder cells) (eg, culture in a culture dish inoculated with feeder cells).
  • Day 4 Transfer cells to G-Rex 10 and incubate with TexMACS TM supplemented with IL-7 10 ng / ml and IL 15 5 ng / ml.
  • Day 7 Replace half of the culture with TexMACS TM with IL-7 10 ng / ml and IL 15 5 ng / ml.
  • Day 10 Replace half of the culture with IL-7 10 ng / ml and IL 15 5 ng / ml TexMACS TM.
  • Day 14 The culture is finished.
  • the gene transfer efficiency was 8% for culture method 1 (A-1) and 18.1% for culture method 2 (A-2) (Fig. 6A), and culture method 2 was significantly higher than that of conventional culture method 1. Improvement of gene transfer efficiency was observed. That is, it was demonstrated that the novel culture method is effective in improving the efficiency of gene transfer.
  • the proliferation rate of CAR-T cells from day 7 was 20-fold with anti-iditopes antibody stimulation (A-2) and 13-fold with conventional OKT3 / anti-CD28 antibody stimulation (A-1). (Fig. 6B).
  • the new culture method overcomes the weaknesses of the transposon method (gene transfer efficiency and cell viability / cell proliferation rate are lower than those of the viral vector method), and will expand the clinical application of CAR therapy using the transposon method. I can say.
  • the novel culture method is highly versatile and can be applied to the preparation of CAR cells by the viral vector method or the like, and its utility value is great.
  • Day 1 Stimulate with anti-iditope antibody coated plate (B-2, culture method 2) or OKT3 / anti-CD28 antibody coated plate (B-1, culture method 1 (conventional method)).
  • Day 4 Transfer cells to a 24-well plate and incubate with TexMACS TM supplemented with IL-7 10 ng / ml and IL 15 5 ng / ml.
  • Day 7 Culture finished
  • the gene transfer efficiency was 20.5% for anti-iditope antibody stimulation (B-2, culture method 2) and 3.58% for OKT3 / anti-CD28 antibody stimulation (B-1, culture method 1 (conventional method)) (Fig. 8A). ), Compared with the conventional method of OKT3 / anti-CD28 antibody stimulation, anti-iditopes antibody stimulation showed a significant improvement in gene transfer efficiency.
  • the number of CAR-T cells was 550,000 for anti-iditopes antibody stimulation (B-2) and 180,000 for OKT3 / anti-CD28 antibody stimulation (B-1) (Fig. 8B). / Compared with anti-CD28 antibody stimulation, anti-iditope antibody stimulation showed a significant improvement in CAR-T cell number.
  • Method (1) Preparation of activated T cells (1-1) Preparation of anti-CD3 antibody / anti-CD28 antibody coated (sensitized) plate
  • Anti-CD3 antibody and anti-CD28 antibody were diluted with PBS to 1 mg / ml and diluted with PBS. Add to a 24-well uncoated plate to 0.5 ml / well. The plate is allowed to stand in an incubator at 37 ° C for 2-4 hours. Aspirate antibody-diluted PBS and wash once with 1 ml PBS per well.
  • PBMCs Mononuclear cells
  • PBMCs Mononuclear cells
  • 5 ⁇ g of a plasmid vector expressing the CAR target antigen is introduced by electroporation (nucleofection), and culture is started in an incubator.
  • Day 1 After irradiation, it is used as a feeder cell.
  • Day 1 Stimulate with anti-iditope antibody coated plates or target antigen gene-introduced PBMCs (feeder cells).
  • Day 4 Transfer cells to G-Rex 10 and incubate with TexMACS TM supplemented with IL-7 10 ng / ml and IL 15 5 ng / ml.
  • Day 7 Replace half of the culture with TexMACS TM with IL-7 10 ng / ml and IL 15 5 ng / ml.
  • Day 10 Replace half of the culture with IL-7 10 ng / ml and IL 15 5 ng / ml TexMACS TM.
  • Day 14 The culture is finished.
  • the number of CAR-T cells is increased by cell stimulation (protective action of transgenic cells damaged during electroporation) by expression of co-stimulating molecules, cytokine stimulation by culture microenvironment, and the like. It can be expected that the increase and the efficiency of gene transfer will increase further.
  • the transgenic cells and irradiated viral peptide-added activated T cells are mixed, floated on TexMACS TM supplemented with IL-7 10 ng / ml and IL15 5 ng / ml, and cultured in a 24-well plate in a 37 ° C incubator.
  • Day 1 Stimulate with anti-iditope antibody coated plates or target antigen gene-introduced PBMCs (feeder cells).
  • Day 2-5 If necessary, replace half of the culture with IL-7 10 ng / ml and IL 15 5 ng / ml TexMACS TM.
  • Day 7 Cells are collected and counted.
  • the number of CAR-T cells is further increased by cell stimulation by the expression of co-stimulating molecules, cytokine stimulation by the culture microenvironment, and relatively gentle cell stimulation from virus-specific T cell receptors. And further increase in gene transfer efficiency can be expected.
  • a decrease in allogeneic reactivity effect that can be expected for virus-specific CTL
  • the possibility of using CAR-T cells derived from a third party due to this and the stimulation of virus antigen receptors in the body by a virus in the body. Persistency may increase, and further improvement in safety and increase in therapeutic effect are expected.
  • ⁇ Culture method 6 (improvement of culture method 5)> 1.
  • Method Day 0 Isolate mononuclear cells (PBMCs) from peripheral blood. After irradiating a part ( 6 PBMC 1x10), add viral peptides (PepTivator CMV pp65, PepTivator AdV5 Hexon, PepTivator EBV EBNA-1 and PepTivator EBV BZLF1 50 ng each) and incubate at 37 ° C for 30 minutes.
  • viral peptides PepTivator CMV pp65, PepTivator AdV5 Hexon, PepTivator EBV EBNA-1 and PepTivator EBV BZLF1 50 ng each
  • Activated T cells are prepared from the remaining PBMCs according to the method (1).
  • Day 1 Stimulate with anti-iditope antibody coated plates or target antigen gene-introduced PBMCs (feeder cells).
  • Day 2-5 If necessary, replace half of the culture with IL-7 10 ng / ml and IL 15 5 ng / ml TexMACS TM.
  • Day 7 Cells are collected and counted.
  • virus peptides PepTivator CMV pp65, PepTivator AdV5 Hexon, PepTivator EBV EBNA-1 and PepTivator EBV BZLF1 50 ng each
  • Day 10 Replace half of the culture with IL-7 10 ng / ml and IL 15 5 ng / ml TexMACS TM.
  • Day 14 The culture is finished.
  • the above culture method 6 makes it possible to obtain CAT-T cells by collecting blood once, and has an advantage that the burden on the patient is reduced. Further, the culture method 6 can be expected to further improve the gene transfer efficiency.
  • the gene transfer efficiency or cell proliferation rate when preparing CAR cells is improved. That is, the present invention makes it possible to efficiently prepare a larger number of CAR cells, and can contribute to improving the therapeutic results of CAR therapy, expanding the scope of application of CAR therapy, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/JP2020/042187 2019-11-20 2020-11-12 キメラ抗原受容体遺伝子改変リンパ球の調製方法 WO2021100585A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021558324A JPWO2021100585A1 (enrdf_load_stackoverflow) 2019-11-20 2020-11-12

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-209891 2019-11-20
JP2019209891 2019-11-20

Publications (1)

Publication Number Publication Date
WO2021100585A1 true WO2021100585A1 (ja) 2021-05-27

Family

ID=75981284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/042187 WO2021100585A1 (ja) 2019-11-20 2020-11-12 キメラ抗原受容体遺伝子改変リンパ球の調製方法

Country Status (2)

Country Link
JP (1) JPWO2021100585A1 (enrdf_load_stackoverflow)
WO (1) WO2021100585A1 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024024551A1 (ja) * 2022-07-26 2024-02-01 国立大学法人京都大学 シェディング構造を有する人工受容体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017061615A1 (ja) * 2015-10-08 2017-04-13 国立大学法人名古屋大学 キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法
JP2017535284A (ja) * 2014-11-05 2017-11-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
JP2018516092A (ja) * 2015-04-06 2018-06-21 サブドメイン リミテッド ライアビリティ カンパニー 新規結合ドメイン含有ポリペプチドおよびその使用
JP2018519842A (ja) * 2015-07-21 2018-07-26 ノバルティス アーゲー 免疫細胞の有効性および増大を改善する方法
WO2019027850A1 (en) * 2017-07-29 2019-02-07 Juno Therapeutics, Inc. CELL EXPANSION REAGENTS EXPRESSING RECOMBINANT RECEPTORS
JP2019527553A (ja) * 2016-07-29 2019-10-03 ジュノー セラピューティクス インコーポレイテッド 抗ｃｄ１９抗体に対する抗イディオタイプ抗体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535284A (ja) * 2014-11-05 2017-11-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
JP2018516092A (ja) * 2015-04-06 2018-06-21 サブドメイン リミテッド ライアビリティ カンパニー 新規結合ドメイン含有ポリペプチドおよびその使用
JP2018519842A (ja) * 2015-07-21 2018-07-26 ノバルティス アーゲー 免疫細胞の有効性および増大を改善する方法
WO2017061615A1 (ja) * 2015-10-08 2017-04-13 国立大学法人名古屋大学 キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法
JP2019527553A (ja) * 2016-07-29 2019-10-03 ジュノー セラピューティクス インコーポレイテッド 抗ｃｄ１９抗体に対する抗イディオタイプ抗体
WO2019027850A1 (en) * 2017-07-29 2019-02-07 Juno Therapeutics, Inc. CELL EXPANSION REAGENTS EXPRESSING RECOMBINANT RECEPTORS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024024551A1 (ja) * 2022-07-26 2024-02-01 国立大学法人京都大学 シェディング構造を有する人工受容体

Also Published As

Publication number Publication date
JPWO2021100585A1 (enrdf_load_stackoverflow) 2021-05-27

Similar Documents

Publication Publication Date Title
JP6857360B2 (ja) キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法
TWI823829B (zh) 靶向血液惡性腫瘤之嵌合抗原受體（ｃａｒ），其組合物及使用方法
AU2020204448A1 (en) Compositions and methods for immunotherapy
JP6971986B2 (ja) 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
JP6853514B2 (ja) 炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球
WO2024199197A1 (zh) 功能增强型工程化免疫细胞及其制备和应用
EP4334346A2 (en) Chimeric receptors and methods of use thereof
JP7057975B2 (ja) 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球
WO2021100585A1 (ja) キメラ抗原受容体遺伝子改変リンパ球の調製方法
US20180369282A1 (en) Gene-modified lymphocytes expressing chimeric antigen receptor in which production of inflammatory cytokines is inhibited
KR20230022868A (ko) 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
JP7576547B2 (ja) Ｃａｒ発現免疫細胞を含む細胞集団の製造方法
US20220184124A1 (en) Methods and reagents for characterizing car t cells for therapies
JP7531603B2 (ja) Ｃｄ２８ｈドメイン含有キメラ抗原受容体および使用方法
JP7075595B2 (ja) チオプリン高感受性キメラ抗原受容体遺伝子改変リンパ球
EP4428229A1 (en) Method for producing car-t cells
WO2020085480A1 (ja) 高効率な遺伝子改変細胞の作製方法
JP2022171485A (ja) キメラ抗原受容体を発現する遺伝子改変ｔ細胞の調製方法
CN115960257B (zh) 靶向IL13Rα2的经优化的嵌合抗原受体及其用途
RU2816370C2 (ru) Устойчивые к ритуксимабу химерные антигенные рецепторы и пути их применения
WO2025085721A1 (en) Chimeric receptors and uses thereof
JP2023504196A (ja) 胎盤由来の同種ｃａｒ－ｔ細胞およびその使用
CN113728001A (zh) 抗利妥昔单抗嵌合抗原受体及其用途
JPWO2020004337A1 (ja) Ｃｄ３７特異的キメラ抗原レセプター

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20889865

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021558324

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20889865

Country of ref document: EP

Kind code of ref document: A1